Today’s biopharma news highlights how new data could reduce treatment burden, improve excipient information sharing, and shape future options for patients with difficult-to-treat cancers.
|Articles|November 6, 2007
Jeffrey D. Bloss Joins Xencor as Chief Medical Officer
Author(s)BioPharm International Editors
Xencor (Monrovia, CA) has appointed Jeffrey D. Bloss, MD, chief medical officer. Bloss will direct Xencor's clinical and preclinical development strategies.
Advertisement
Xencor (Monrovia, CA) has appointed Jeffrey D. Bloss, MD, chief medical officer. Bloss will direct Xencor's clinical and preclinical development strategies. He will be responsible for building the company's clinical development team and for the design and implementation of studies to evaluate the company's pipeline of novel antibody and protein therapeutics. Most recently, Bloss was the vice president of clinical development at Onyx Pharmaceuticals, Inc., where he led the development for sorafenib.
Advertisement
Related to this article
Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.
IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.
Insulin efsitora alfa-gobe (Onswik) cuts injections from 365 to 52 a year for adults with type 2 diabetes, per its new FDA approval.
Genentech is paying Earendil Labs $55 million upfront in a deal worth over $1.5 billion to develop bispecific antibodies for hard-to-treat cancers.
Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
AstraZeneca's sBLA for durvalumab combined with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer, based on the Phase 3 VOLGA trial, has a PDUFA date expected in the fourth quarter of 2026.
Advertisement
Advertisement